<DOC>
	<DOC>NCT01901120</DOC>
	<brief_summary>This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.</brief_summary>
	<brief_title>Long-Term Specified Drug Use-results Survey of Betanis Tablets</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients who administer mirabegron for treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder and also who have no treatment history of mirabegron.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BetanisÂ®</keyword>
	<keyword>mirabegron</keyword>
	<keyword>Overactive Bladder</keyword>
</DOC>